SCHEMBL4800513

SCHEMBL4800513

COC(=O)c1ccc(OCCCO/N=C\c2cn(Cc3ccccc3)c3ccccc23)cc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
ALDH1A1 P00352 5/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
POLB P06746 3/20 0.50
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 1/20 0.50
CASP6 P55212 1/20 0.49
RCE1 Q9Y256 1/20 0.49
GCGR P47871 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
THRB P10828 1/20 0.46
BACE1 P56817 1/20 0.46
SENP7 Q9BQF6 1/20 0.45
PLA2G1B P04054 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
PLA2G2A P14555 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799000 1.00 MAPT (0.52) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4798983 1.00 MAPT (0.52) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4800762 0.92 ALDH1A1 (0.50) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4800748 0.92 ALDH1A1 (0.50) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4796882 0.83 MEN1 (0.45) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4796874 0.83 MEN1 (0.45) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4798109 0.81 MAOB (0.42) MAPTALDH1A1KMT2AGAAPLA2G2A
SCHEMBL4798124 0.81 MAOB (0.42) MAPTALDH1A1KMT2AGAAPLA2G2A
SCHEMBL4798181 0.79 MAPT (0.45) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL4798169 0.79 MAPT (0.45) MAPTALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US disclosed
EP-1667670-A1 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-14 EP disclosed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US disclosed
WO-2005030192-A1 4- (1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY) -BENZIOC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS WYETH (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119326-A1 Substituted aryloximes IDO2, TDO2, IDO1 MAPT 4402/4885ALDH1A1 304/4885HPGD 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.